Quviviq
(Daridorexant)ApprovedSmall molecule
Idorsia Pharmaceuticals Ltd.Daridorexant is used to help people who have trouble falling asleep or staying asleep. It works by blocking a chemical in the brain that promotes wakefulness, allowing people to sleep better.[2] Quviviq is currently approved and in use across 13 indications[4].[1]
Quviviq is one of 384 small molecule programs targeting Cognitive impairment. It is currently in Approved.
13
Indications
32
Total Trials
14
Active Trials
383
Competitors
1
FDA Application
NDA/BLA/ANDA regulatory filings
3
Patents
Pipeline
Status by Indication[4][1]
Indication
Showing 10 of 13 indications
Competition
Competitive Landscape
119 competitors in Chronic Obstructive Pulmonary Disease
#DrugCompanyPhaseTrials
1Quviviq
Idorsia Pharmaceuticals Ltd.Approved
Lunsekimig
SanofiPhase 3
CM310
KKeymed Biosciences Co.Ltd
Phase 3
Sildenafil ODT
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Phase 2
Astegolimab
RochePhase 3
Tozorakimab
AstraZenecaPhase 3
HSK39004
Haisco Pharmaceutical Group Co., Ltd.Phase 2
RLS-0071
RReAlta Life Sciences, Inc.
Phase 2
Calciferol
Jazz PharmaceuticalsPreclinical
Duragesic
CCephalon
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Insomnia8 trials
Show 5 more trials
Alzheimer disease2 trials
Daridorexant for Alzheimer Disease Prevention
Recruiting·—·Phase 2·NCT07213349·240 enrolled
Delirium2 trials
Single Dose1 trial
17 more indications
Midazolam1 trial
Statin1 trial
Menopause1 trial
Comparing Digital Therapy, Trazodone, and Daridorexant for Menopause-Related Insomnia Symptoms
Recruiting·—·Phase 4·NCT07136415·1,000 enrolled
Sleep1 trial
Efficacy and Safety1 trial
Phase 11 trial
TED1 trial
Elderly1 trial
Liver Cirrhosis1 trial
Insomia Disorder1 trial
Insomnia Disorders1 trial
Alcohol Use Disorder1 trial
Regulatory
FDA Approval Timeline[5]
Apr 7, 2022
QUVIVIQ
NDA NDA214985
Sources
References
- [1]
- [2]MedlinePlus Drug Information — Quviviq drug information. U.S. National Library of Medicine, National Institutes of Health.
- [3]
- [4]Open Targets Platform — Drug–disease associations for Daridorexant. EMBL-EBI & Wellcome Sanger Institute.
- [5]
- [6]
- [7]
Details
Drug Info
Quick Facts
- Mechanism of Action
- Orexin Receptor 2 Antagonist; Orexin Receptor Antagonist; Orexin Receptor 1 Antagonist[3]
- Modality
- Small molecule[3]
- Highest Phase
- Approved[1]
- Company